The neo (neomycin-resistance) gene of transposon TnS encodes the enzyme neomycin phosphotransferase II (EC 2.7.1.95), which confers resistance to various aminoglycoside antibiotics, including kanamycin and G418. The gene is widely used as a selectable marker in the transformation of organisms as diverse as bacteria, yeast, plants, and animals. We found a mutation that involves a glutamic to aspartic acid conversion at residue 182 in the protein encoded by the chimeric neomycin phosphotransferase II genes of several commonly used transformation vectors. The mutation substantially reduces phosphotransferase activity but does not appear to affect the stability of the neomycin phosphotransferase II mRNA or protein. Plants and bacteria transformed with the mutant gene are less resistant to antibiotics than those transformed with the normal gene. A simple restriction endonuclease digestion distinguishes between the mutant and the normal gene.
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The aminoglycoside phosphotransferases belong to a clinically important group of proteins that enable bacteria to grow in the presence of selected aminoglycoside antibiotics, including kanamycin, neomycin, and G418. These enzymes, which are plasmid or transposon encoded, inactivate the antibiotics by catalyzing the transfer of the terminal phosphate of ATP to the drug (1) . Neomycin phosphotransferase II (NPTII; EC 2.7.1.95) is one of the most well-known members of this group. The neomycin-resistance (neo) gene of TnS that encodes this enzyme is the most widely used selectable marker in the transformation of organisms including yeast (2) , Dictyostelium discoideum (3) , mammals (4) , and plants (5) . The gene is usually modified to contain a promoter and terminator that can function in the recipient host. Cells that receive and properly express such chimeric constructs can be selected by using antibiotic concentrations that inhibit the growth of cells not containing the resistance gene.
The aminoglycoside 3'-phosphotransferases exhibit 30-36% amino acid sequence homology except in a region near the carboxyl terminus, where the homology is 60-70% (6) . It has been suggested that the catalytic functions of binding ATP and transferring the terminal phosphate are performed at the more conserved region (7) . We have found a mutation in this region of chimeric NPTII genes of several widely used transformation vectors. The mutation causes reduced NPTII enzyme activity, resulting in a decreased ability of transformants to grow in the presence of elevated concentrations of antibiotic. (10) . Polysomal RNA from tobacco was isolated according to Goldberg et al. (11) . ELISA for NPTII was performed according to Firoozabady et al. (12) . The procedure for tobacco leaf disc transformation follows that of Horsch et al. (13) .
MATERIALS AND METHODS
NPTII Activity Assay. Samples were from the same leaves that were used for the antibiotic tolerance assay in Fig. 2 . NPTII was determined by ELISA. Total protein was determined by the Bradford protein assay (Bio-Rad).
mutant gene is not due to a decrease in the level of gene expression. NPTII protein amounts were determined in the leaf tissues used for preparing the leaf discs shown in Fig. 2 (Fig. 3A, lanes 1-3) showed a higher NPTII phosphorylating activity than that of extracts containing the mutant enzyme (Fig. 3A, lanes 4 and 5) . On the other hand, Northern blot analysis of polysomal RNAs from the same tissues (Fig. 3B ) revealed low NPTII mRNA levels in plants with high NPTII enzyme activity and high levels of mRNA in plants with undetectable or barely detectable enzyme activity (compare lanes 1-3 with lanes 4 and 5 in Fig. 3 A and B ). ELISA analysis (Fig. 3C) (Fig. 4) . Both enzymes conferred resistance to kanamycin at 100 and 200 .ug/ml. However, at 400,ug/ml, bacteria containing the mutant enzyme displayed retarded growth compared to bacteria carrying the normal enzyme (Fig. 4 A and B) . The difference in growth rate was more dramatic when G418 was used as the selective agent. Cells containing the normal enzyme detoxified G418 at all concentrations tested, while cells containing the mutant enzyme exhibited poor growth in G418 at 20 t.g/ml and no growth in G418 at 30,ug/ml during a 9-hr culture period (Fig.   4 C and D NPTII 3' noncoding region containing the Xho II site is present in the structure of the chimeric gene, an additional 392-bp fragment is generated. As indicated in Fig. 1 , the G T substitution at nucleotide 2096 results in the loss of an Xho II site. Therefore, digestion of the mutant chimeric gene with Xho II will produce a 638-bp fragment in place of the 246-and 392-bp fragments. In Fig. 5 Observations of homologies between the amino acid sequences of kinases and phosphotransferases have led to the suggestion that both classes of proteins have catalytic domains of similar function and general location within the structure of the protein (7). Biochemical and mutational analyses have shown that the catalytic domain of the protein kinases resides in the carboxyl-terminal portion of the protein (for reviews, see refs. 22 and 23). The conserved region of amino acid sequence shared by the phosphotransferases and the kinases localizes the catalytic domain of the phosphotransferases to the carboxyl terminus. The invariant aspartic acid and asparagine residues, present in all phosphotransferases (7) and kinases (24) , are found here. The glutamic acid residue at position 182 in NPTII is found in this region and is conserved in all known type II aminoglycoside 3'-phosphotransferases (25) .
No mutations have been described that affect the biochemical behavior of the NPTII or related phosphotransferase enzymes. Using chemical modification of amino acid residues in NPITII followed by analysis of enzyme activity, J. P. Greer and M. H. Perlin (personal communication) have implicated histidine-188 with the binding of kanamycin and tyrosine-218, -244, or -257 with the binding of ATP.
On a practical level, the reduced activity of the mutant NPTII enzyme clearly affects the ability of transformants to withstand antibiotic selection pressure from kanamycin or its analogs. A properly functioning selectable marker is critical for maximizing the potential for detection of the few transformed cells in a population after a transformation procedure. Based on our analysis of plant and animal transformation vectors, it is likely that many laboratories, working in diverse disciplines, are using a mutant NPTII gene encoding a phosphotransferase of low activity. Digestion with the endonuclease Xho II provides a simple test to quickly determine if the mutation is present in the NPTII gene.
